Latest Racing News

BetMakers Technology Group reports solid Q3 FY25 financial gains alongside a strategic binding agreement to acquire Nevada’s LVDC, expanding its global racing technology footprint.

BetMakers Technology Group is poised to expand its North American footprint by acquiring LVDC, Nevada’s exclusive pari-mutuel wagering provider, targeting an initial A$4 million in annual revenue.

PointsBet has secured a significantly improved acquisition proposal from MIXI, lifting the cash offer by 13.2% to $1.20 per share and postponing the shareholder vote to June 25. The move intensifies the takeover battle amid ongoing regulatory approvals and a rival bid from Betr Entertainment.

MTM Critical Metals has achieved a breakthrough in recovering high-grade antimony from U.S.-sourced electronic waste, surpassing traditional mine grades and supporting U.S. efforts to secure critical metal supplies amid global supply disruptions.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.

RAS Technology Holdings has boosted its annualised recurring revenue to $21.1 million, driven by strategic acquisitions and a flurry of new contracts. The company’s expanding global footprint signals strong momentum heading into FY26.

Turners Automotive Group has delivered a record FY25 profit and dividend, showcasing resilience amid economic challenges and positioning itself to exceed FY28 profit goals ahead of schedule.

BetMakers Technology Group reports a strong FY25 trading update, driven by enhancements to its Apollo racing suite and preparations for the GTX wagering platform launch, signaling robust momentum heading into FY26.

Delta Lithium has significantly expanded its Yinnetharra Lithium and Tantalum Project by acquiring the Aston Project, adding 1,750 square kilometres to its tenure and reinforcing its dominant position in Western Australia's Upper Gascoyne region.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.